Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction

Title:Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction

Volume: 11 Issue: 2

Author(s): Hakan Gunes and Tarik Kivrak

Affiliation:

Keywords: Eltrombopag, idiopathic thrombocytopenic purpura, myocardial infarction, thrombosis.

Abstract: Eltrombopag is a non-peptide thrombopoietin receptor agonist. Eltrombopag has originally been developed for conditions where therapy for thrombocytopenia is needed. Secondary to eltrombopag have been reported thrombotic events, chest pain, acute renal failure, neutropenia, ascites, retinal exudates, antiphospholipid syndrome. In this case, we present a 53 year-old patient who had diagnosis of Idiopathic Thrombocytopenic Purpura (ITP) for 30 years with splenectomy. He’s still having low thrombocyte counts despite the classical ITP therapy. He was treated with eltrombopag for the last 2 months and had inferior myocardial infarction despite that having no additional risk factors for coronary heart disease.

Cite this article as:

Gunes Hakan and Kivrak Tarik, Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction, Current Drug Safety 2016; 11 (2) . https://dx.doi.org/10.2174/1574886311207040255